Table 2.
Laboratory examination of COVID-19 patients with or without history of CVD.
| Laboratory examination | History of CVD n = 109 | No history of CVD n = 2,445 | P-Value |
|---|---|---|---|
| White blood cell count (109/L), median (IQR) | 5.80 (5.85) | 5.40 (2.3) | 0.001 |
| Neutrophil count (109/L), median (IQR) | 3.73 (3.02) | 3.13 (1.6) | <0.001 |
| Lymphocyte count (109/L), mean ± SD | 1.11 ± 0.50 | 1.45 ± 0.64 | <0.001 |
| C-reactive protein (mg/L), median (IQR) | 2.57 (14.22) | 1.20 (2.79) | 0.039 |
| Fibrinogen (g/L), mean ± SD | 2.84 ± 0.74 | 2.93 ± 0.80 | 0.288 |
| Thrombin time (S), mean ± SD | 15.09 ± 1.11 | 15.08 ± 1.33 | 0.954 |
| Prothrombin time (S), median (IQR) | 12.99 (1.94) | 12.65 (1.25) | 0.756 |
| Activated partial thromboplastin time (S), median (IQR) | 27.48 (4.62) | 27.62 (3.91) | 0.634 |
| D-dimer (mg/L), median (IQR) | 0.71 (0.9) | 0.38 (0.5) | 0.002 |
| Glutamic pyruvic transaminase (IU/L), mean ± SD | 25.22 ± 22.59 | 31.04 ± 33.61 | 0.074 |
| Glutamic oxaloacetic transaminase (IU/L), mean ± SD | 24.19 ± 20.85 | 22.20 ± 24.42 | 0.402 |
| Albumin (g/L), median (IQR) | 33.90 (7.75) | 37.20 (5.7) | <0.001 |
| Blood urea nitrogen (mmol/L), median (IQR) | 5.09 (3.44) | 4.09 (1.64) | 0.019 |
| Serum creatinine (umol/L), median (IQR) | 67.20 (41.60) | 62.30 (20) | 0.425 |
| Creatine kinase (IU/L), median (IQR) | 45.70 (70.78) | 43.10 (34.8) | 0.507 |
| Creatine kinase isoenzymes (IU/L), mean ± SD | 11.58 ± 11.74 | 9.27 ± 8.55 | 0.007 |
| Lactate dehydrogenase (IU/L), mean ± SD | 194.78 ± 55.18 | 175.26 ± 54.35 | <0.001 |
Data are reported as mean ± SD or median (IQR). T-test or Mann–Whitney U-test was used to calculate P-value when appropriate. Data of the following indicators were missing C-reactive protein in 1 case, Fibrinogen in 10 cases, Prothrombin time in 10 cases, Activated partial thromboplastin time in 10 cases, D-dimer in 10 cases, Creatine kinase in 1 case, Creatine kinase isoenzymes in 1case, Lactate dehydrogenase in 1case.